![]()
|
|
||||||||
J. Biol. Chem., Vol. 276, Issue 40, 36902-36908, October 5, 2001
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
§¶,
,
,
,
,
, and
From the
Department of Neuroimmunology,
Max-Planck-Institute of Neurobiology, D-82152 Martinsried,
Germany, § Institute for Clinical Neuroimmunology,
Ludwig-Maximilians-University, 81377 Munich, Germany,
Institute
for Clinical and Molecular Virology, University
Erlangen-Nürnberg, 91054 Erlangen, Germany,
** Department of Internal Medicine III and Institute for
Clinical Immunology, University of Erlangen-Nürnberg, 91054 Erlangen, Germany, 
Hôpital Purpan,
31059 Toulouse, France, §§ INSERM U429,
Hôpital Necker, 75015 Paris, France and ¶¶ INSERM
U520, Institut Curie, 75248 Paris, France
Received for publication, March 26, 2001, and in revised form, June 19, 2001
| |
ABSTRACT |
|---|
|
|
|---|
The protein tyrosine kinase ZAP-70 plays a
pivotal role involved in signal transduction through the T cell
receptor and CD2. Defects in ZAP-70 result in severe combined
immunodeficiency. We report that Herpesvirus saimiri, which
does not code for a ZAP-70 homologue, can replace this tyrosine kinase.
H. saimiri is an oncogenic virus that transforms human T
cells to stable growth based on mutual CD2-mediated activation.
Although CD2-mediated proliferation of ZAP-70-deficient uninfected T
cells was absent, we could establish H. saimiri-transformed
T cell lines from two unrelated patients presenting with ZAP-70
deficiencies. In these cell lines, CD2 and CD3 activation were restored
in terms of [Ca2+]i, MAPK activation, cytokine
production, and proliferation. Activation-induced tyrosine
phosphorylation of The tyrosine kinase ZAP-70 is essential for activation of mature T
cells via CD3. An autosomal recessive form of severe combined immunodeficiency in humans has been described as resulting
from mutations within the gene encoding ZAP-70. This deficiency
is characterized by an absence of CD8+ T cells and an
increased number of nonfunctional CD4+ T cells with a
mature phenotype in the periphery. These CD4+ T cells are
unresponsive to either antigenic stimulation in vivo or CD2-
and CD3-mediated activation in vitro (1-3).
According to current concepts, binding of antigen to the T cell
receptor (TCR)1 initiates a
cascade of early signaling events, which includes activation of the
protein tyrosine kinases (PTKs) of the Src family. These PTKs
phosphorylate the immune-receptor tyrosine-based activation motifs,
which are present in all the chains of the CD3- ZAP-70 not only plays a crucial role in CD3-mediated T cell activation
but also in CD2-mediated activation (5, 6). CD2 constitutes the
so-called alternative pathway of T cell activation (7); simultaneous
triggering of two distinct epitopes on CD2 by two mAbs induces T cells
to proliferate and secrete lymphokines in the absence of antigen and
antigen-presenting cells.
A mutual activation via CD2 is the basis of the autocrine growth of
human T cells transformed by Herpesvirus saimiri (8). H. saimiri is an oncogenic virus that induces leukemia and
lymphoma in New World and Old World primates (9). This virus transforms human T cells to stable growth in vitro (10). Human T cells transformed by this virus retain essential properties of native T
cells. In particular they display a structurally and functionally intact TCR and show a grossly unaltered sensitivity to different apoptotic pathways. The preservation of an intact TCR distinguishes H. saimiri-transformed T cells from T cells transformed with
human T cell leukemia virus-1, which tend to lose their TCRs (11).
An essential difference between native uninfected T cells and H. saimiri-transformed T cells is their differential requirement for
CD2-mediated activation. Native uninfected T cells are activated via
CD2 only by certain pairs of mAbs but not by the binding of CD2 to its
ligand CD58. In contrast, H. saimiri-transformed T cells are
activated by interaction with CD58-bearing cells or, alternatively, by
a single mAb to the T11.1 epitope of CD2 provided the mAb is
cross-linked (8).
The purpose of this study was to obtain further insights into the
mechanisms responsible for the transformation of T cells by H. saimiri. To this end, we studied activation of H. saimiri-transformed T cell lines established from primary T cells
of two severe combined immunodeficiency patients with ZAP-70
deficiencies. We report herein that H. saimiri transforms
ZAP-70-deficient T cells to stable growth and can overcome the
requirement of ZAP-70 for T cell activation. CD2 and CD3 activation of
these T cell lines induces activation of MAPK, increase of
[Ca2+]i, and cytokine production.
Zap-70-deficient Patients, T Cell Culture, and Transformation
with H. saimiri--
We studied two unrelated severe combined
immunodeficiency patients presenting with defects in ZAP-70 expression.
The first patient has been described previously (6) and has a
homozygous deletion in the zap-70 gene, which leads to a
complete absence of ZAP-70 protein expression. The second patient had
clinical phenotype typical for ZAP-70 deficiency (3) and biochemically a complete lack of ZAP-70 protein expression (Fig. 1), but the genetic
abnormality is not yet defined. Peripheral blood mononuclear cells from both ZAP-70-defective patients were activated with phorbol 12-myristate 13-acetate + ionomycin and expanded in IL-2 for a
few days. Subsequently the cells were infected with H. saimiri strain C488 and cultured as described (11). As controls,
we used several H. saimiri-transformed T cell clones and
lines (ES-8T, SS-8T, Wi-4T, DT, and HT) established from control donors
and the transformed cell line CB15 obtained from cord blood.
Flow Cytometry--
mAbs directed to CD3, CD4, CD8, CD69,
TCR CD2- and CD3-mediated Cytokine Production--
For CD2-mediated
activation, the mAb 39C1.5, which recognizes the T11.1 epitope (Coulter
Immunotech, Hamburg, Germany), was applied, and for CD3-mediated
activation, the mAb OKT-3 was applied. The mAbs were cross-linked with
murine A20 cells, which express high amounts of Fc receptors.
Alternatively, the stimulating mAbs were cross-linked by absorbing to
the plastic plates. As a control a mAb recognizing CD58 (purified from
the hybridoma TS2/9.1.4.3, which was obtained from ATCC) was used. The
Src family-specific inhibitor PP2 (Calbiochem, Bad Soden, Germany) and
the Syk/ZAP-70-specific inhibitor piceatannol (Sigma) were applied. PP2
was dissolved in Me2SO at 20 mg/ml (66 mM) and used at a final concentration of 10 µM. Piceatannol was dissolved in Me2SO at 10 mg/ml (41 mM) and used at a final concentration of 10 µg/ml. Both inhibitors were used immediately after dissolving. The T
cells were preincubated with the diluted inhibitors in the incubator
for 30 min and subsequently stimulated. At the applied concentrations,
the inhibitors were not cytotoxic, and the solvent Me2SO
did not interfere significantly with T cell activation. About 5 × 104 T cells were seeded per well in a volume of 200 µl of
medium without IL-2. All experiments were performed in triplicate.
Supernatants were collected 24 h after activation. Production of
TNF- Proliferation Assay--
H. saimiri-transformed T
cells were seeded in 96-well flat-bottom plates at a density of
2.5 × 104 or 1 × 105
cells/well in 200 µl of culture medium without IL-2. The anti-CD2 mAb
39C1.5 or control rat Ig was added at 4 µg/ml at four time points.
Three days later, 0.2 µCi of [3H]thymidine (Amersham
Pharmacia Biotech) was added for another 16 h. Cultures were
harvested and analyzed with the direct Immunoprecipitation and Western Blot Analysis--
H.
saimiri-transformed T cells or primary T cells prepared as
described (6) were left unactivated or activated for 3 min at 37 °C
in the presence of the anti-TCR mAb UCHT1 (ascitic fluid at 1/1000) or
a combination of the two anti-CD2 mAbs X11 and D66 (kindly given by Dr
L. Boumsel, INSERM U448, France). Cells were then lysed in lysis buffer
(20 mM Tris-HCl, pH 7.4, 140 mM NaCl, 2 mM EDTA, 50 mM NaF, 1% Nonidet P-40, 0.5%
sodium deoxycholate, 0.1% SDS, 100 µM
Na3VO4, and protease inhibitors) for 20 min at 4 °C. Nuclei and cell debris were removed by centrifugation. Protein concentrations were determined in the post-nuclear lysates using a
Bio-Rad kit. For immunoprecipitations, the same amount of lysate was
precleared at 4 °C by rocking with mouse or rabbit purified IgG for
1 h at 4 °C. Then protein G-Sepharose beads were added and the
nonspecific immunoprecipitates recovered by centrifugation. After this
preclearing, lysates were incubated overnight with anti-Syk Abs (Santa
Cruz, sc-1077), with anti-
The following first antibodies were used: anti-phosphotyrosine mAb
4G10; anti-Syk mAb (Upstate Biotechnology Inc.) or anti-Syk polyclonal
Ab (Santa Cruz); anti-ZAP-70 mAb (Transduction Laboratory) and
polyclonal Ab (kindly given by B. Malissen, Marseille, France); anti-
The antibody/antigen complexes were visualized by an enhanced
chemiluminescence detection system according to the manufacturer's instruction (ECL, Amersham Pharmacia Biotech) using anti-mouse Ig or
anti-rabbit Ig Abs coupled to horseradish peroxidase as secondary antibodies.
For quantitative Western blot, an anti-mouse Ig coupled to alkaline
phosphatase (Dako, Hamburg) and the substrate CDP-star (Roche Molecular
Biochemicals) were applied. The quantification was done with the
LumiImager (Roche Molecular Biochemicals). Afterward, Coomassie Blue
staining of the blotted membranes assessed equal loading of the
different lanes.
Measurement of
[Ca2+]i--
[Ca2+]i was
determined as described previously (6). The T cells were activated via
CD3 with the mAb OKT3 and via CD2 with the mAbs 39C1.5 and 6F10.3.
Cross-linking was achieved with goat anti-mouse Ig or goat anti-rat Ig, respectively.
Growth Transformation of ZAP-70-deficient T Cells by H. saimiri--
After infection with H. saimiri, stable
growing cells were obtained from both of the ZAP-70-deficient donors.
The transformed T cell lines were designated ZAP-70-1T and ZAP-70-2T.
These cells had the phenotype of mature activated CD4+ T
cells expressing CD2, CD3, and the TCR Overexpression of Syk in ZAP-70-deficient Transformed T
Cells--
We analyzed the expression of the ZAP-70-related PTK Syk in
primary and transformed T cells. Syk was not over-expressed in the
primary T cells from the two patients (Fig. 2). We noted that H. saimiri-transformed T cell lines and uninfected T cell lines from
control donors showed a similar expression level of ZAP-70 and of Syk
(Fig. 2).
However, when ZAP-70-deficient transformed T cells were infected with
H. saimiri, the outgrowing transformed T cells displayed a
strong overexpression of Syk (Fig. 2, A and B).
This observation was confirmed using a quantitative Western blot (Fig.
2C). It showed that Syk was expressed at least 20-fold more
than in other transformed cell lines obtained from control donors,
which exhibit low, barely detectable, and variable levels of Syk.
CD3 and CD2 Triggering Induced an Increase in
[Ca2+]i in H. saimiri-transformed
ZAP-70-deficient T Cells--
To analyze CD3-mediated
[Ca2+]i, the mAb OKT-3 was used with and without
cross-linking. In two independent experiments, the increase in
[Ca2+]i triggered by CD3-mediated activation was
found to be defective in primary T cells derived from ZAP-70-deficient patients in that no or only a marginal [Ca2+]i
was observed (Fig. 3C), in
accordance with Refs. 1 and 2). In contrast, CD3 activation
induced a strong increase in [Ca2+]i in
ZAP-70-defective T cells after transformation (Fig. 3D) in
each of four independent experiments with the H. saimiri-transformed T cell line ZAP-70-1T.
The complete lack of CD2-induced [Ca2+]i in
primary ZAP-70-deficient T cells has been described previously in
detail (6). Here we analyzed the [Ca2+]i in
H. saimiri-transformed T cells after CD2 activation. Fig. 3
(compare panels A and B) demonstrates that
ZAP-70-deficient T cells are rendered responsive to CD2 activation
after transformation with H. saimiri.
It is a unique feature of H. saimiri-transformed T cells to
become activated via CD2 with one cross-linked mAb directed to the T11.1 epitope (8). Our study shows that ZAP-70-deficient H. saimiri-transformed T cells respond with an increase of
[Ca2+]i after cross-linking of the T11.1 epitope
(Fig. 3F).
H. saimiri Restores Activation-induced ERK
Phosphorylation--
CD2- and CD3-mediated phosphorylation of ERK1 and
ERK2 was defective in the ZAP-70-defective nontransformed T cells (Fig. 4). By contrast, in ZAP-70-deficient
H. saimiri-transformed T cells the MAP kinases ERK1 and ERK2
are activated upon CD2 or CD3 activation as reflected by their
phosphorylation (Fig. 4). The activation-induced phosphorylation of
ERK1 and ERK2 was comparable in cell lines established from the
ZAP-70-deficient patients and from control donors.
Defective Phosphorylation of the TCR- Activation-mediated Phosphorylation of Syk--
Because we
found that Syk was heavily overexpressed in ZAP-70-deficient H. saimiri-transformed T cells, we studied whether the Syk expressed
in the transformed cell lines could be activated. Triggering of CD2 and
CD3 induced tyrosine phosphorylation of Syk in H. saimiri-transformed cell lines established from both control
donors and ZAP-70-deficient patients (Fig. 5).
Cytokine Production via CD3 and CD2 Activation--
Because
primary ZAP-70-deficient T cells do not respond to CD2 and CD3
triggering in terms of cytokine production (6), the ZAP-70-deficient
H. saimiri-transformed T cells ZAP-70-1T and ZAP-70-2T
derived from both patients were analyzed for CD2- and CD3-mediated
cytokine production. To this end, a mAb recognizing the T11.1 epitope
on CD2 or the CD3-specific mAb OKT-3 was added and cross-linked either
with Fc receptor-expressing A20 cells (Fig.
6, A and B) or
after binding to the microtiter plate (Fig. 6C). As control,
a mAb directed to CD58, which is abundantly expressed on H. saimiri-transformed T cells, was applied. The H. saimiri-transformed T cell lines obtained from both of the
ZAP-70-defective patients responded to this activation via CD2 or CD3
in a manner similar to the other ZAP-70-expressing transformed T cells
with increased production of TNF- Autocrine Growth Is Mediated via Mutual CD2-mediated
Activation--
Because ZAP-70-deficient H. saimiri-transformed T cells were responsive to CD2- and
CD3-mediated T cell activation, we analyzed whether their autocrine
growth was mediated via CD2. To this end we cultured ZAP-70-deficient
H. saimiri-transformed T cells and control T cells in the
presence of a mAb that blocks the CD2-CD58 interaction. In the presence
of this mAb, the spontaneous proliferation of the ZAP-70-expressing and
ZAP-70-deficient transformed T cells was reduced to a similar extent
(Fig. 8).
We demonstrate that the infection by H. saimiri of T
cells from two patients with ZAP-70 deficiencies restores T cell
activation by CD2 and CD3. H. saimiri does not encode for a
gene that has homology to ZAP-70 (13), but it can replace this tyrosine
kinase. Different cellular and biochemical events occurring as a
consequence of TCR or CD2 activation were analyzed to gain insight into
the mechanisms used by the virus to substitute for ZAP-70.
When comparing a series of wild type H. saimiri-transformed
T cells with the patient-derived T cell lines, we found that Syk, which
belongs to the same family of PTK as ZAP-70, was heavily overexpressed
in the ZAP-70-deficient transformed T cells. In contrast,
primary T cells from the same patients expressed low levels of Syk that
are comparable to the ones observed in mature T cells (14). These low
levels of Syk could not substitute for ZAP-70 for CD2- or CD3-triggered
activation (6).
In H. saimiri-transformed cell lines, the enormously
overexpressed Syk becomes tyrosine-phosphorylated upon CD2 and CD3
activation. This suggests that Syk overexpression in the
ZAP-70-deficient lines may be responsible for the CD2- and CD3-induced
activation observed in these cell lines. Syk has indeed been shown to
be able to substitute to some extent for ZAP-70 in other models. In
ZAP-70 In this study, we showed that upon transformation with
H. saimiri, ZAP-70-deficient T cells became responsive to
CD3 and CD2 activation in terms of an increase in
[Ca2+]i, MAPK activation, cytokine production,
and cell proliferation, whereas these responses were impaired in the
primary T cells from the ZAP-70-deficient patients. In contrast, in the
study published by Noraz et al. (17), CD3-induced MAPK
activation and proliferation were not fully restored in the
ZAP-70-deficient T cell blasts expressing high levels of Syk. Moreover,
the CD3-induced increase in [Ca2+]i obtained in
the ZAP-70 T cell blasts presented unique features compared with
those obtained in normal T cell blasts. Altogether, this
suggests that the overexpression of Syk, as we observed in this study,
can partially but not completely explain the restoration of CD2- and
CD3-mediated signaling events after transformation with H. saimiri.
Remarkably, as reported in primary T cells from the ZAP-70-deficient
patients (6), CD2 or CD3 activation of the transformed cell lines from
the patients did not induce any tyrosine phosphorylation of the The mechanisms underlying the overexpression of Syk in ZAP-70-deficient
transformed cells are unclear. Infection with H. saimiri and
subsequent transformation as such are not responsible for the
overexpression of Syk, because in none of the transformed T cells from
normal donors was Syk expressed at higher levels than in noninfected T
cells. One possible explanation for Syk overexpression could be the
following. During the process of growth transformation after
infection with H. saimiri, there is a selective advantage
for cells that can be activated by CD2 because stable growth
after infection with H. saimiri is based on CD2-mediated activation. Indeed, we demonstrate that in the ZAP-70-deficient transformed T cells, as in ZAP-70-expressing T cell lines (8), an
autocrine growth was mediated via CD2 activation. This suggests that after H. saimiri infection of ZAP-70-deficient T
cells there is a selective growth advantage for T cells expressing high
levels of Syk. During T cell ontogeny, Syk expression is
down-regulated; however, there is a small population of TCR We observed that a specific inhibitor of the Syk tyrosine kinase family
blocked CD2-induced production of TNF- As previously discussed overexpression of Syk cannot fully explain the
restoration of CD2 and CD3 activation observed in the ZAP-70-deficient
T cells transformed by H. saimiri. It is possible that viral
proteins cooperate with Syk to restore CD2 and CD3 responsiveness. In
human transformed T cells, H. saimiri persists episomally,
and only two viral genes are transcribed constitutively in human
transformed T cells (18). Both corresponding proteins, tyrosine
kinase-interacting protein (Tip) and H. saimiri
transformation-associated protein of C strains (STP-C), are absolutely
required for growth transformation (19) and interact with signaling
proteins. Tip binds to Lck and is phosphorylated by Lck (20). In most
(21-23) but not all assay systems (24) Tip activated Lck. Tip also
activates STAT-1, STAT-3, and NF-AT-dependent transcription
(22, 25). A model has been proposed in which Lck phosphorylates Tip and the phosphorylated Tip then recruits STATs (26).
The other viral protein essential for transformation, STP-C, binds to
Ras, favoring its active GTP-bound state and stimulating MAPK activity
(27). STP-C also binds to TRAFs (tumor necrosis factor
receptor-associated factor) leading to NF- The substitution of ZAP-70 by H. saimiri transformation is a
special feature of this virus and not a mere consequence of growth transformation, because ZAP-70-deficient T cells that have been transformed by human T cell leukemia virus-1 essentially continue to
display the same activation deficits that are characteristic of native
ZAP-70-deficient T cells (5, 32). Moreover, in contrast to H. saimiri, human T cell leukemia virus-1 down-regulates the
expression of ZAP-70 (12).
In conclusion, our study shows that transformation by H. saimiri replaces ZAP-70 for most CD2- and CD3-mediated activation events. This replacement of ZAP-70 was not achieved with a genetically engineered virus but rather with the wild type virus that does not code
for a ZAP-70 homologue. To our knowledge this is the first report
showing that a wild type virus can restore CD2- and CD3-mediated
activation in signaling-deficient human T cells. Because
autocrine activation is dependent on CD2 activation, the virus needs to
restore this to ensure growing of the latently infected cells.
This study shows that thereby CD3 responsiveness is also restored,
suggesting that CD3-mediated proliferation shares the signaling
pathways with CD2-mediated proliferation.
remained defective. The transformed cells
expressed very high levels of the ZAP-70-related kinase Syk. This
increased expression was not observed in the primary T cells from the
patients and was not due to the transformation by the virus because
transformed cell lines established from control T cells did not present
this particularity. In conclusion, wild type H. saimiri can
restore CD2- and CD3-mediated activation in signaling-deficient human T
cells. It extends our understanding of interactions between the
oncogenic H. saimiri and the infected host cells.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
complex. This allows
the recruitment of ZAP-70, which is then phosphorylated and activated
and subsequently phosphorylates a number of key substrates including
LAT, SLP-76, and Vav. These tyrosine kinase reactions are required for
CD3-induced mobilization of intracellular free calcium
([Ca2+]i) and activation of the
Ras/mitogen-activated protein kinase (MAPK), leading to cytokine
production and proliferation, responses that are all defective in the
absence of ZAP-70 (4).
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

, TCR
, and HLA-DR, and labeled isotype controls
were obtained from Becton Dickinson (Heidelberg, Germany). CD2
expression was detected with supernatant of the hybridoma
TS2/18.1.1 (ATCC, Manassas, VA) and a fluorescein isothiocyanate-labeled goat anti-mouse-IgG F(ab)2 fragment
(Dianova, Hamburg, Germany). Flow cytometry analysis was performed on a FACScalibur or FACScan® flow cytometer (Becton Dickinson).
, interferon-
, and IL-2 was determined by ELISA.
counter Matrix TM96 (Packard
Instrument Co.).
mAb (Santa Cruz, sc-1239), or anti-ZAP-70
Abs. Specific immunoprecipitates were recovered by the addition of
protein G-Sepharose beads for 1 h and were washed three times in
lysis buffer. Immunoprecipitates or post-nuclear cell lysates were then
run on standard SDS-polyacrylamide gel electrophoresis and transferred
to a polyvinylidene difluoride membrane (Immobilon-P, Millipore).
Nonspecific binding was blocked with 5% bovine serum albumin in
phosphate-buffered saline, 0.05% Tween.
-chain mAb (Santa Cruz); anti-p56Lck and
anti-p59Fyn Abs (Santa Cruz); anti-phospho-p44/42 MAPK mAb
(New England Biolabs); and anti-ERK2 polyclonal Abs (Santa Cruz Biotechnology).
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

along with the activation markers CD69 and HLA-DR (Fig.
1A for ZAP-70-1T and
data not shown for ZAP-70-2T). Phenotypically, the ZAP-70-deficient
transformed T cells could not be distinguished from other
CD4+ H. saimiri-transformed cell lines. Western
blot experiments performed on both total cell lysates and ZAP-70
immunoprecipitates demonstrated that the H. saimiri-transformed T cell lines did not recover ZAP-70 expression
(Figs. 1B and 2, A
and B). The expression of the two Src-PTKs, Fyn and Lck, was
normal in the H. saimiri-transformed T cell lines from both
patients (Fig. 1C).

View larger version (32K):
[in a new window]
Fig. 1.
Phenotype of H. saimiri-transformed ZAP-70-deficient T cells.
A, the surface phenotype of the H. saimiri-transformed T cell line ZAP-70-1T obtained from the first
patient was analyzed for the expression of the indicated surface
markers. The open histogram represents the isotype control,
and the closed graphs represent the specific staining for
the indicated marker. B, an immunoprecipitation with
anti-ZAP-70 demonstrates the absence of the ZAP-70 protein in the
transformed T cell lines ZAP-70-1T and ZAP-70-2T obtained from the
two patients analyzed. C, expression of the Src kinases Lck
and Fyn were analyzed by Western blot in the two ZAP-70-deficient
transformed T cell lines ZAP-70-1T and ZAP-70-2T and in the
ZAP-70-expressing control cell line SS-8T.

View larger version (64K):
[in a new window]
Fig. 2.
Overexpression of Syk. A,
expression of ZAP-70 and Syk was analyzed by Western blot in
uninfected and transformed T cells derived from the first patient.
I65 and EM-P indicate T cell blasts from normal
donors. B, Western blot analysis of Syk and ZAP-70 in the
ZAP-70-2T-transformed T cell line derived from the second patient.
C, expression of Syk of the ZAP-70-1T cell line and of
three control cell lines were analyzed by quantitative Western blot as
described under "Experimental Procedures." To assess equal loading,
a Coomassie staining of the blotted membrane was performed.
SS-8T, CB15, DT, and ES-8T are H. saimiri-transformed T cells from control donors.

View larger version (23K):
[in a new window]
Fig. 3.
CD2- and CD3-mediated
[Ca2+]i. A,
ZAP-70-deficient uninfected T cell blasts from patient 1 were incubated
with the anti-CD2 mAbs 6F10.3 (4 µg/ml, dilution 1:50 in 20 µl) and
39C1.5 (4 µg/ml, dilution 1:50 in 20 µl). B, H. saimiri-transformed T cells from patient 1 were activated with the
mAbs 6F10.3 (4 µg/ml, dilution 1:50 in 6.6 µl) and 39C1.5 (4 µg/ml, dilution 1:50 in 6.6 µl). C, ZAP-70-deficient
uninfected T cell blasts from patient 1 were incubated with the
anti-CD3 mAb OKT3. D, H. saimiri-transformed T
cells from patient 1 were activated with the anti-CD3 mAb OKT-3.
E, control T cells were activated with the mAb OKT3.
F, H. saimiri-transformed T cells from patient 1 were activated with the anti-CD2 mAb mAb 6F10.3. mAbs 6F10.3 and 39C1.5
were applied at a concentration of 4 µg/ml (dilution 1:50). mAb OKT3
was used at a concentration of 5 µg/ml (dilution 1:200). The
arrows in each panel indicate the addition of
Abs. The right-most arrow in each panel indicates
the addition of the cross-linking of anti-mouse Ig (10 µg/ml,
dilution 1:150) or anti-rat Ig (10 µg/ml, dilution 1:200).

View larger version (25K):
[in a new window]
Fig. 4.
MAPK phosphorylation. Primary
CD4+ T cells from patient 2 or a control donor or H. saimiri T cell lines from patient 2 or a control donor were
activated with anti-CD3
(UCHT1) or anti-CD2 mAbs
(X11+D66) for 3 min at 37 °C. Active ERKs were
detected with anti-phospho-ERK Abs (upper panels) by Western
blot analysis. Total Erk-2 expression was checked and is shown in the
lower panels.
Chain in ZAP-70-deficient
H. saimiri-transformed T Cells--
Because H. saimiri
restored MAPK activation and [Ca2+]i, we analyzed
to what extent the CD2- and CD3-dependent signal cascades were restored. CD2 or CD3 triggering of H. saimiri-transformed T cells induced no phosphorylation of
(Fig. 5). By contrast, activation of cell
lines established from control donors readily induced a phosphorylation
of the
chain (Fig. 5).

View larger version (56K):
[in a new window]
Fig. 5.
Syk and
phosphorylation. H. saimiri-transformed T cells
from the two ZAP-70-deficient patients and of a control H. saimiri T cell line were activated as described in the legend for
Fig. 4. After lysis,
or Syk were immunoprecipitated, and their
tyrosine phosphorylations were checked by Western blot analysis using
the antiphosphotyrosine-specific mAb 4G10. The total quantity of
and Syk immunoprecipitated were revealed with anti-
- and
anti-Syk-specific Abs, respectively (lower panels). Because
of the strong overexpression of Syk in the transformed
ZAP-70-deficient T cell lines, five times more protein of the control
cell line SS-8T had to be used for the immunoprecipitation with Syk.
Additionally, longer exposure times (15 s for the ZAP-70-deficient and
5 min for the control cell line) were used to visualize Syk in all
analyzed cell lines.
(Fig. 6) and interferon-
(data
not shown). PP2, an inhibitor of Src family kinases, and piceatannol,
an inhibitor of Syk/ZAP-70 kinases, blocked the CD2-induced production
of IL-2 and TNF-
of both the ZAP-70-deficient and control H. saimiri-transformed T cell lines (Fig.
7).

View larger version (23K):
[in a new window]
Fig. 6.
CD2- and CD3-mediated activation of cytokine
production intact after transformation. The H. saimiri-transformed T cell lines from the first (A) and
the second patient (B and C) were activated with
the mAb OKT3 directed to CD3 or the mAb 39C1.5 directed to CD2.
Cross-linking of these mAbs was achieved with Fc receptor-bearing A20
cells (A and B) or by coating of the microtiter
plate with the mAb (C). The mAb to CD58, rat Ig, and medium
were used as controls. Supernatants were collected 24 h after
activation, and the amount of TNF-
was determined by ELISA.

View larger version (20K):
[in a new window]
Fig. 7.
Inhibitors of Src and Syk/ZAP-70 kinases
interfere with CD2-mediated activation. H. saimiri-transformed T cell lines from the first and second patient
as well as the transformed control cell line SS-8T were preincubated in
the presence of 10 µM PP2 or 10 µg/ml piceatannol and
then activated with the CD2-specific mAb 39C1.5 cross-linked by A20
cells. Supernatants were collected after 24 h and analyzed by
ELISA.

View larger version (27K):
[in a new window]
Fig. 8.
Autocrine proliferation of the transformed
cells is mediated via CD2. The spontaneous proliferation of the
transformed T cell lines derived from both patients (ZAP-70-1T and
ZAP-70-2T) and two control cell lines was analyzed. A rat-derived mAb
to CD2 (39C1.5) or rat Ig was added. One to three independent
experiments were performed per cell line, and the mean of these
experiments is presented. The proliferation in the absence of added Ig
was set at 100%, and the proliferation in the presence of the added Ig
was calculated.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
/
mice, thymocyte development can be restored by Syk expression (15), indicating that ZAP-70 and Syk have overlapping functions. In the P116 Jurkat clone lacking both Syk and ZAP-70 expression, tyrosine phosphorylation of several proteins and NF-AT activation are restored by Syk expression (16). Moreover, it has been
shown in T cell blasts obtained from two siblings presenting with
ZAP-70 deficiency and overexpressing Syk after expansion that CD3
activation was restored to some extent (17). The results obtained in
our present study on ZAP-70-deficient H. saimiri-transformed T cells present some similarities to but also has properties distinct from the ones obtained on blasts from ZAP-70-deficient patients.
chain, showing that Syk does not induce exactly the same signaling
events as ZAP-70 in T cells. These data are consistent with another
study showing that
phosphorylation is defective in the P116 Jurkat
cells transfected with Syk (16). It has been proposed that the Src
homology-2 domains of ZAP-70 might protect the phosphorylated
immune-receptor tyrosine-based activation motifs of the
chain from
dephosphorylation (4). Because this defect remains in H. saimiri-transformed T cells overexpressing Syk, this argues that
Syk cannot replace ZAP-70 for the protection of
from dephosphorylation.

CD4+ T cells that expresses a high level of Syk (14). This
population may be the one that is transformed by H. saimiri
and has a selective advantage to grow.
and IL-2 in H. saimiri-transformed T cells from both normal donor and
ZAP-70-deficient patients. These results argue that ZAP-70, in the
control H. saimiri T cell lines, and Syk, in the
ZAP-70-deficient T cell lines, are implicated in T cell activation. Src
tyrosine kinases are also involved in both cases, because PP2 inhibited
T cell activation of H. saimiri-transformed T cell lines.
These results support the notion that this virus utilizes T cell
activation pathways to ensure stable growth of the infected T cells.
B activation (28).
Oncogenic Ras can replace STP-C for T cell transformation (29). All of
these studies indicate that H. saimiri proteins may
contribute to modifications of the signaling pathways. Normal T
cellular activation pathways are not only preserved during
transformation but, as we show here, are even reconstituted. H. saimiri reconstituted the CD2-mediated activation pathway,
probably because the virus needs this to ensure the growth of the
infected T cells. Remarkably, the CD3-mediated activation pathways were
also restored, although CD3-mediated activation is not needed for
stable growth because antigen-specific T cell clones can be stably
transformed independently of the presence of their antigen (11). The
reconstitution of the CD3 pathway along with the CD2 pathway probably
reflects the fact that CD2 and CD3 signaling pathways share common
features as already described (30, 31).
| |
ACKNOWLEDGEMENTS |
|---|
We are grateful to I. Müller-Fleckenstein, M. Schmidt, and N. Lezot for expert technical assistance and to Dr. U. Welge-Lüssen for advice in quantitative Western blot analysis. We thank Drs. W. Klinkert and C. Linington for valuable comments on the manuscript.
| |
FOOTNOTES |
|---|
* This work was supported by the Deutsche Forschungsgemeinschaft (SFB 466 and SFB 571) and the Wilhelm Sander-Stiftung (97.081.1). The Institute of Clinical Neuroimmunology is supported by the Hermann and Lilly Schilling Foundation.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
¶ To whom correspondence should be addressed: Dept. of Neuroimmunology, Max-Planck-Institute of Neurobiology, D-82152 Martinsried, Germany. Tel.: 49-89-8578-3519; Fax: 49-89-8995-0163; E-mail: meinl@neuro.mpg.de.
Published, JBC Papers in Press, July 19, 2001, DOI 10.1074/jbc.M102668200
| |
ABBREVIATIONS |
|---|
The abbreviations used are: TCR, T cell receptor; Ab, antibody; mAb, monoclonal antibody; MAPK, mitogen-activated protein kinase; PTK, protein tyrosine kinase; IL, interleukin; ELISA, enzyme-linked immunosorbent assay; ERK, extracellular signal-regulated kinase; STAT, signal transducers and activators of transcription; TNF, tumor necrosis factor; Tip, tyrosine kinase-interacting protein; STP-C, H. saimiri transformation-associated protein of C strains; NF, nuclear factor.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Chan, A. C., Kadlecek, T. A., Elder, M. E., Filipovich, A. H., Kuo, W. L., Iwashima, M., Parslow, T. G., and Weiss, A. (1994) Science 264, 1599-1601 |
| 2. | Arpaia, E., Shahar, M., Dadi, H., Cohen, A., and Roifman, C. M. (1994) Cell 76, 947-958 |
| 3. | Hivroz, C., and Fischer, A. (1994) Curr. Biol. 4, 731-733 |
| 4. | Chan, A. C., Desai, D. M., and Weiss, A. (1994) Annu. Rev. Immunol. 12, 555-592 |
| 5. | Ueno, H., Matsuda, S., Katamura, K., Mayumi, M., and Koyasu, S. (2000) Eur. J. Immunol. 30, 78-86 |
| 6. | Meinl, E., Lengenfelder, D., Blank, N., Pirzer, R., Barata, L., and Hivroz, C. (2000) J. Immunol. 165, 3578-3583 |
| 7. | Meuer, S. C., Hussey, R. E., Fabbi, M., Fox, D., Acuto, O., Fitzgerald, K. A., Hodgdon, J. C., Protentis, J. P., Schlossman, S. F., and Reinherz, E. L. (1984) Cell 36, 897-906 |
| 8. | Mittrücker, H. W., Müller-Fleckenstein, I., Fleckenstein, B., and Fleischer, B. (1992) J. Exp. Med. 176, 909-913 |
| 9. | Knappe, A., Feldmann, G., Dittmer, U., Meinl, E., Nisslein, T., Wittmann, S., Mätz-Rensing, K., Kirchner, T., Bodemer, W., and Fickenscher, H. (2000) Blood 95, 3256-3261 |
| 10. | Biesinger, B., Müller-Fleckenstein, I., Simmer, B., Lang, G., Wittmann, S., Platzer, E., Desrosiers, R. C., and Fleckenstein, B. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 3116-3119 |
| 11. | Meinl, E., Hohlfeld, R., Wekerle, H., and Fleckenstein, B. (1995) Immunol. Today 16, 55-58 |
| 12. | Weil, R., Levraud, J. P., Dodon, M. D., Bessia, C., Hazan, U., Kourilsky, P., and Israel, A. (1999) J. Virol. 73, 3709-3717 |
| 13. | Albrecht, J. C., Nicholas, J., Biller, D., Cameron, K. R., Biesinger, B., Newman, C., Wittmann, S., Craxton, M. A., Coleman, H., Fleckenstein, B., and Honess, R. W. (1992) J. Virol. 66, 5047-5058 |
| 14. | Chu, D. H., van Oers, N. S., Malissen, M., Harris, J., Elder, M., and Weiss, A. (1999) J. Immunol. 163, 2610-2620 |
| 15. | Gong, Q., White, L., Johnson, R., White, M., Negishi, I., Thomas, M., and Chan, A. C. (1997) Immunity 7, 369-377 |
| 16. | Williams, B. L., Schreiber, K. L., Zhang, W., Wange, R. L., Samelson, L. E., Leibson, P. J., and Abraham, R. T. (1998) Mol. Cell. Biol. 18, 1388-1399 |
| 17. | Noraz, N., Schwarz, K., Steinberg, M., Dardalhon, V., Rebouissou, C., Hipskind, R., Friedrich, W., Yssel, H., Bacon, K., and Taylor, N. (2000) J. Biol. Chem. 275, 15832-15838 |
| 18. | Fickenscher, H., Bökel, C., Knappe, A., Biesinger, B., Meinl, E., Fleischer, B., Fleckenstein, B., and Bröker, B. M. (1997) J. Virol. 71, 2252-2263 |
| 19. | Duboise, S. M., Guo, J., Czajak, S., Desrosiers, R. C., and Jung, J. U. (1998) J. Virol. 72, 1308-1313 |
| 20. | Biesinger, B., Tsygankov, A. Y., Fickenscher, H., Emmrich, F., Fleckenstein, B., Bolen, J. B., and Bröker, B. M. (1995) J. Biol. Chem. 270, 4729-4734 |
| 21. | Wiese, N., Tsygankov, A. Y., Klauenberg, U., Bolen, J. B., Fleischer, B., and Bröker, B. M. (1996) J. Biol. Chem. 271, 847-852 |
| 22. | Hartley, D. A., Amdjadi, K., Hurley, T. R., Lund, T. C., Medveczky, P. G., and Sefton, B. M. (2000) Virology 276, 339-348 |
| 23. | Hartley, D. A., Hurley, T. R., Hardwick, J. S., Lund, T. C., Medveczky, P. G., and Sefton, B. M. (1999) J. Biol. Chem. 274, 20056-20059 |
| 24. | Jung, J. U., Lang, S. M., Jun, T., Roberts, T. M., Veillette, A., and Desrosiers, R. C. (1995) J. Virol. 69, 7814-7822 |
| 25. | Lund, T. C., Garcia, R., Medveczky, M. M., Jove, R., and Medveczky, P. G. (1997) J. Virol. 71, 6677-6682 |
| 26. | Hartley, D. A., and Cooper, G. M. (2000) J. Biol. Chem. 275, 16925-16932 |
| 27. | Jung, J. U., and Desrosiers, R. C. (1995) Mol. Cell. Biol. 15, 6506-6512 |
| 28. | Lee, H., Choi, J. K., Li, M., Kaye, K., Kieff, E., and Jung, J. U. (1999) J. Virol. 73, 3913-3919 |
| 29. | Guo, J., Williams, K., Duboise, S. M., Alexander, L., Veazey, R., and Jung, J. U. (1998) J. Virol. 72, 3698-3704 |
| 30. | Howard, F. D., Moingeon, P., Moebius, U., McConkey, D. J., Yandava, B., Gennert, T. E., and Reinherz, E. L. (1992) J. Exp. Med. 176, 139-145 |
| 31. | Ley, S. C., Davies, A. A., Druker, B., and Crumpton, M. J. (1991) Eur. J. Immunol. 21, 2203-2209 |
| 32. | Taylor, N., Bacon, K. B., Smith, S., Jahn, T., Kadlecek, T. A., Uribe, L., Kohn, D. B., Gelfand, E. W., Weiss, A., and Weinberg, K. (1996) J. Exp. Med. 184, 2031-2036 |
This article has been cited by other articles:
![]() |
E. Heck, U. Friedrich, M. U. Gack, D. Lengenfelder, M. Schmidt, I. Muller-Fleckenstein, B. Fleckenstein, A. Ensser, and B. Biesinger Growth transformation of human T cells by herpesvirus saimiri requires multiple tip-lck interaction motifs. J. Virol., October 1, 2006; 80(20): 9934 - 9942. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Sorokina, J. J. Merlo Jr., and A. Y. Tsygankov Molecular Mechanisms of the Effect of Herpesvirus saimiri Protein StpC on the Signaling Pathway Leading to NF-{kappa}B Activation J. Biol. Chem., April 2, 2004; 279(14): 13469 - 13477. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. S. Torres, D. A. Zapata, A. Pacheco-Castro, J. L. Rodriguez-Fernandez, C. Cabanas, and J. R. Regueiro Contribution of CD3{gamma} to TCR regulation and signaling in human mature T lymphocytes Int. Immunol., November 1, 2002; 14(11): 1357 - 1367. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |